Merus B.v.
Clinical trials sponsored by Merus B.v., explained in plain language.
A clinical-stage biopharmaceutical company developing bispecific antibody therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a Two-Target antibody shrink Hard-to-Treat cancers?
Disease control Recruiting nowThis trial is testing an experimental drug called petosemtamab (MCLA-158) in people with advanced solid tumors, including colorectal, head and neck, and lung cancers. The drug is a bispecific antibody designed to block two cancer-related proteins, EGFR and LGR5. Researchers want …
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for head and neck cancer: experimental drug petosemtamab enters final testing
Disease control Recruiting nowThis Phase 3 trial tests a new drug called petosemtamab against standard treatments (cetuximab, methotrexate, or docetaxel) in 600 adults with advanced head and neck cancer that has spread or come back. Participants must have already tried immunotherapy and chemotherapy. The main…
Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New combo therapy aims to boost survival in head and neck cancer
Disease control Recruiting nowThis study tests whether adding petosemtamab to the standard immunotherapy pembrolizumab helps people with advanced head and neck cancer live longer. About 700 adults with PD-L1 positive cancer that has spread or come back will receive either the combination or pembrolizumab alon…
Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC